Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin versus sitagliptin for benign thyroid nodule size reduction in newly diagnosed type 2 diabetes
2019-000676-42Phase 4Active
- Sponsor
- Pointe-à-Pitre University Hospital
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of metformin and sitagliptin in type 2 diabetes mellitus (T2DM) and benign thyroid nodule (2 arms), sponsored by Pointe-à-Pitre University Hospital. Primary endpoint: Decrease in thyroid nodule size at 2 years. Started Jan 2020; status: active.
02
Drugs
metforminsitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)benign thyroid nodule
Beyond the preview
Go deeper on 2019-000676-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000676-42.